Experts

Antoine Andremont is currently Emeritus Professor at the Paris Diderot University Medical School, France, a scientific advisor at the French Ministry of Higher Education, Research and Innovation, and serves as an expert witness for the French National Highest Judiciary Court (Cour de Cassation). He is also the co-founder and a senior scientific advisor at biotechnology company Da Volterra - which he created in 2000 to research and understand the impact of antibiotics on the intestinal flora microbiota, the development and

John N van den Anker is a renowned paediatric consultant based at the Children’s National Medical Center Washington, DC, whose research has resulted in a much more evidence-based use of antibacterial agents such as aminoglycosides, cephalosporins, penicillins, meropenem, and vancomycin in children. John holds many titles including, the Evan and Cindy Jones Endowed Professor of Paediatric Clinical Pharmacology at Children’s National Medical Center; the Eckenstein-Geigy Distinguished Professor in Paediatric Pharmacology and Pharmacometrics at the University of Basel Children’s Hospital in

Jesús Rodríguez-Baño is Professor of Medicine at the University of Seville and Head of the Infectious Diseases division at Hospital Universitario Virgen Macarena in Seville, Spain. He is also Scientific Chair of the Spanish Network for Research in Infectious Diseases (REIPI), which is funded by Instituto de Salud Carlos III, and President-Elect of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Jesús is a medical doctor and specialist in internal medicine, who gained his PhD in medicine in

Michael Barbachyn is the Brummel Chair and Professor of Organic Chemistry at Calvin College, Michigan, US, and an independent consultant at Barbachyn Consulting. Michael has over 27 years’ experience in medicinal chemistry as a research scientist following periods at Upjohn, Pharmacia & Upjohn, Bristol-Myers Squibb, Pharmacia, Pfizer and AstraZeneca, focused on anti-infectives. Michael also has 12 years’ pharmaceutical industry management experience as an associate director and director in antibacterial medicinal chemistry at Pharmacia and then Pfizer; and as a director

Greg Basarab is Principal Research Officer and Associate Director at the University of Cape Town (UCT), Drug Discovery and Development Centre (H3D). He is Head of drug metabolism and pharmacokinetics (DMPK) and pharmacology groups located at Groote Schuur Hospital, Head of Institute of Infectious Diseases and Molecular Medicine, and Head of Medicinal Chemistry groups within the UCT Chemistry Department. He lectures at the UCT Medical School on Drug Disposition and Pharmacology. Greg worked in various aspects of antibacterial and antifungal

Alex van Belkum is currently Scientific Director of Microbiology Research at bioMérieux, a diagnostics company based in the South of France. He is also a fellow of the American Academy of Microbiology. Alex is a microbiologist in the data analytics unit of bioMérieux with a prime interest in next generation sequencing, and the use of other data-rich technologies in clinical microbiology. His long career has been dedicated to the research of molecular epidemiology, molecular and culture-based diagnostics and antimicrobial resistance

Julia Bielicki is currently a consultant in Paediatric Infectious Diseases and Infection Prevention and Control at the University of Basel Children’s Hospital. She is also an active researcher with the Paediatric Pharmacology Division at the University of Basel Children’s Hospital and a Senior Lecturer with the Paediatric Infectious Diseases Research Group at St George’s University of London. Furthermore, Julia is involved in developing a national antimicrobial stewardship programme in Switzerland. Julia’s research focuses on observational and interventional studies that aim

Helen Boucher is currently Director of the Infectious Diseases Fellowship Program, Director of the Heart Transplant and Ventricular Assist Device Infectious Diseases Program, and staff physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center. She is also Professor of Medicine at Tufts University School of Medicine in Boston, Massachusetts. Helen trained as a medical doctor at the University of Texas Medical School, Houston, before completing her internship, residency and chief residency in Internal Medicine at

Pamela Brown has over 30 years’ experience in anti-infective drug discovery gained within the biotech and pharmaceutical sectors. She is currently a consultant in Antibacterial Drug Discovery and Medicinal Chemistry offering independent advice and expertise to small and medium-sized enterprises (SMEs), biotechs and academic institutions. Pam was Director, Medicinal Chemistry at Cantab Anti-infectives for five years following its inception in 2012. There, Pam led the medicinal chemistry team towards novel polymyxins, resulting in a commercial deal with Spero Therapeutics in

Vincent Cattoir is currently Professor of Clinical Microbiology at the University of Rennes 1, as well as a clinical microbiologist at the Bacteriology department of the University Hospital of Rennes, France. Vincent is the Director of the Lab Enterococci, affiliated to the National Reference Center for Antimicrobial Resistance. He is also a senior scientist in the INSERM U1230 Pharmaceutical Biochemistry at the University of Rennes 1, currently focused on regulator RNAs (sRNAs) involved in the pathogenicity and antimicrobial resistance in

Ryan Cirz is Vice President of Infectious Disease Research and Head of the Postdoctoral Program at Achaogen, which focuses on discovering, developing and commercializing innovative antibacterials to treat multi-drug resistant (MDR) Gram-negative infections. Ryan has worked on antibacterial discovery and development at Achaogen for 11 years in roles of increasing seniority, focused almost exclusively on new agents for MDR Gram-negative pathogens. He currently oversees the progress of Achaogen’s early-stage (pre-investigational new drug) pipeline and provides intellectual insight/support to all things

Anthony Coates is the Founder and Chief Scientific Officer of Helperby Therapeutics, a biopharmaceutical company dedicated to developing the next generation of lifesaving antibiotics. Anthony created the company in 2002 and together with colleague Yanmin Hu invented Antibiotic Resistance Breakers (ARBs), a new form of ‘antibiotic renewable’ technology. With existing antibiotic treatments rapidly becoming obsolete, Helperby’s unique antibiotic technology outsmarts highly resistant bacteria by combining ARBs with old antibiotics such as colistin, to create a new and sustainable commercially viable

Matthew Cooper is co-founder, Director and Chief Executive Officer of Inflazome, which develops inflammasome inhibitors for chronic inflammatory diseases. Matt is also Co-Founder and Director of Defensin Therapeutics and Affiliate Professor at Trinity College Dublin. He holds a fractional Professorial Research Fellow appointment at the University of Queensland, where he is Professor of Chemical Biology at the Institute of Molecular Bioscience and, Affiliate Professor in the School of Chemistry and Molecular Biology. Matt obtained his PhD in 1995 in organic

Professor Patrice Courvalin is an internationally recognized expert in the genetics and biochemistry of antibiotic resistance, and in the transfer and heterologous expression of genetic information. He first described and then elucidated, vancomycin resistance in Enterococcus. Patrice’s research has led to a revision of the dogma describing natural dissemination of antibiotic-resistance genes. He and his colleagues demonstrated that a wide variety of pathogenic bacteria can promiscuously exchange genetic material, and proved that conjugation could account for dissemination of genes between

Mike Dawson is a consultant in antimicrobial research, who has spent the last 14 years working in the biotech sector. Mike also has over 20 years’ experience in the pharmaceutical industry gained at GSK. As Head of Biotransformation and Natural Product Chemistry he played leading roles in natural product based drug discovery and the application of biological processes to drug manufacturing. He left GSK in 2003 to set up Novacta Biosystems where, as Chief Scientific Officer (CEO), he led the

Jacques Dumas is a trained chemist with over 20 years’ experience in discovery to clinical proof-of-concept in infectious diseases and oncology. He has been Chief Scientific Officer (CSO) of Tetraphase Pharmaceuticals since July 2015, where he oversees non-clinical sciences and CMC (Chemistry, Manufacturing and Controls) activities to support the company’s product pipeline. Jacques became CSO at Idenix Pharmaceuticals in January 2014, then Vice President at Merck following Merck’s acquisition of Idenix. Between 2007 and 2014, Jacques held several positions at

Barry Eisenstein is the chair of the Scientific and Business Advisory Board of CARB-X, a public-private partnership based at Boston University, devoted to new antimicrobial drug and diagnostic development. Barry received his medical degree from Columbia University and subsequently trained in internal medicine and infectious diseases at the University of North Carolina. He has spent his career in academy and industry, serving as Chief of the Infectious Diseases division at the University of Texas Health Science Center, San Antonio then

Alice Erwin is an independent scientific consultant, providing advice on antibiotic discovery to academic and industrial research groups. She also conducts due-diligence evaluation of antibacterial programmes being evaluated as in-licensing or investing opportunities. Alice is an infectious disease microbiologist with experience in both academic and industrial settings. Her scientific research over the past thirty years has revolved around the structure and function of bacterial membranes, with particular interest in the contribution of lipopolysaccharides to both the pathogenesis and the intrinsic

Domingo Gargallo-Viola is a co-founder and Chief Scientific Officer at ABAC Therapeutics, a leader in pathogen-specific antibiotics that was formerly part of Grupo Ferrer Internacional based in Spain. Domingo has over 30 years’ experience in the discovery and development of anti-infective drugs. At ABAC Therapeutics he is focused on the discovery and development of first-in-class, novel mechanism of action, pathogen-specific, narrow spectrum antibiotics - for the treatment of severe and life-threatening infections due to multidrug-resistant organisms. He is also responsible

Olga Genilloud, Scientific Director and Head of the Microbiology Department at Fundación MEDINA, has over 25 years’ extended research experience in the discovery and biosynthesis of novel natural products antibiotics, obtained in the academic, clinical environment and pharmaceutical sectors. Olga has a PhD in chemistry from the Complutense University of Madrid and has a solid background in industrial microbiology - with expertise in bacterial natural products, molecular biology, ecology and taxonomy, physiology, and production of secondary metabolites. Since 2009, Olga

Mark Goldberger is an independent consultant at Mark Goldberger MD MPH LLC Maryland, USA, where he advises pharmaceutical and biotech companies on the development of infectious diseases products. Before retiring in 2014 and becoming a consultant, Mark spent seven years at AbbVie - formerly part of Abbott - in various senior positons including vice president of regulatory affairs and senior advisor. In these roles he provided regulatory guidance and strategic advice with a focus on US Food and Drug Administration

Trudy Grossman is Senior Director of Biology and Pharmacology at Melinta Therapeutics in New Haven, Connecticut, where she manages a team supporting antibiotic discovery and development. Trudy has worked in microbiology in increasing roles of seniority for over 25 years; most of that time applying the genetics, molecular biology, physiology, and biochemistry of bacteria to the discovery and development of new anti-infectives. This includes tenures at several pharmaceutical companies including Lederle Laboratories where she discovered new genes essential for iron-transport

Bob Hancock is a leading microbiologist in Canada, who has researched and taught at the University of British Columbia (UBC) for nearly 40 years. Bob is currently UBC Killam Professor of Microbiology and Immunology, an Associate Faculty Member at the Wellcome Trust Sanger Institute in the UK, and a Canada Research Chair in Health and Genomics. Bob is focused on designing new therapeutic strategies to treat infections - in the light of increasing antibiotic resistance and a dearth of new

Stephen is Chief Executive Officer of IHMA Europe Sàrl based in Switzerland, a wholly owned affiliate of International Health Management Associates. Since it began operating in 2009, under Stephen’s leadership, IHMA has focused on providing a full suite of technical capabilities and domain expertise in all phases of antimicrobial drug development: drug discovery, clinical development, regulatory approval and commercialization. Before joining IHMA, Stephen held several key positions in the pharmaceutical industry spanning 15 years, focused on antibacterial and antifungal research

Paul Heath is a Professor and Honorary Consultant in Paediatric Infectious Diseases at St George's University Hospital’s NHS Foundation Trust and St George’s, University of London, where he co-leads the Paediatric Infectious Diseases Research Group and is the Director of the Vaccine Institute. Before joining St George’s, Paul was a research fellow in the Oxford Vaccine Group Department of Paediatrics, at John Radcliffe Hospital, Oxford. Paul’s research has focused on the epidemiology of vaccine-preventable diseases, and clinical vaccine trials, particularly

William Hope is Professor of Therapeutics and Infectious Diseases at the University of Liverpool in the UK where he also leads the newly formed Centre for Antimicrobial Pharmacodynamics (CAP). Being part of the university’s Institute of Translational Medicine, this centre provides the pharmacodynamic packages for the development for new antimicrobial agents. William qualified in medicine in 1991, before undertaking specialist training in infectious diseases and clinical microbiology. He completed his PhD in antimicrobial pharmacology in 2006, while undertaking fellowships at

Deborah Hung is a trained physician, chemist and geneticist. She is currently an associate professor in the Department of Molecular Biology at Massachusetts General Hospital and in the Department of Genetics at Harvard Medical School. She is Director of the Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, an infectious disease physician at Brigham and Women’s Hospital and Massachusetts General Hospital and is an attending critical care physician in the Medical Intensive Care Unit at Brigham and

Khalid Islam is the owner of Life Sciences Management GmbH, which consults with start-ups, emerging biotechs and pharma on drug discovery and development. He is also a founding partner of Sirius Healthcare Partners, an advisory boutique in the healthcare sector. Khalid is the Chairman of the Board of Directors of Fennec Pharma and Minoryx Therapeutics, a member of the Board of Directors of Immunomedics and an advisor to the Paris-based venture group Kurma Biofund. Khalid has over 30 years’ experience in

Nachum Kaplan is a co-founder of Nobelex Biotech and has been the Chief Scientific Officer (CSO) since its inception in 2014. Nachum leads on the discovery of new drugs, including overseeing antibacterial compound progression relative to milestone criteria and target product profiles. Nachum is also responsible for all in vitro microbiology studies, in vivo efficacy models and pharmacokinetic/pharmacodynamics (PK/PD) modelling. Before creating Nobelex, Nachum was CSO of Affinium Pharmaceuticals, a drug discovery and development company focused on novel antibiotic therapeutics.

Sushmita Lahiri is Associate Director and a member of the External Innovation, Research Beyond Borders team at Boehringer Ingelheim. This group is the company’s radar for the next wave of innovation and is responsible for identifying emerging science and technologies in Gene therapy, Regenerative medicine, Microbiomes and Infectious diseases. Sushmita is responsible for establishing and leading research collaborations in infectious diseases in partnership with academia and small biotech companies. Prior to this role, Sushmita was Executive Director of Biology at

Jennifer Leeds is Executive Director and Head of West Coast Search and Evaluation, Business Development and Licensing, for the Novartis Institutes for Biomedical Research (NIBR). She is responsible for identifying new science and technology from the western United States for potential partnering with Novartis. Before assuming her current role, Jennifer Leeds was Head of Antibacterial Discovery in the infectious diseases area of NIBR. She was responsible for the strategy and execution of the new antibacterial portfolio from target discovery through

David Lewis is currently the Director of Western Sydney Sexual Health Centre and conjoint Professor at the University of Sydney, Australia. Throughout his career, David has had a special interest in the clinical, microbiological and public health aspects of sexually transmitted infections (STIs) and HIV. David graduated as a medical doctor from the London Hospital Medical College, London University in 1987. Following senior house officer positions in general medicine, haematological oncology, infectious diseases, genitourinary and HIV medicine, David underwent specialist

Jian Li is Head of the Antimicrobial Systems Pharmacology Laboratory at the Biomedicine Discovery Institute, Monash University in Melbourne, Australia. He has also been a Web of Science Highly Cited Researcher in Pharmacology and Toxicology since 2015. Jian has an internationally recognised track record in the pharmacology of polymyxins and the discovery of novel, safer polymyxins. The majority of modern polymyxin pharmacology data were reported by his research group which has led to the first scientifically-based dosing recommendations for intravenous

Sergio Lociuro is Chief Scientific Officer (CSO) at BioVersys AG where he leads the research and development of novel chemical entities that, upon binding to bacterial transcription regulators, are able to control/inhibit expression of resistance to given antibiotic classes, biofilm formation and virulence factors. Sergio has over 30 years’ experience in applied sciences and drug discovery gained in academia and pharma. He has held several positions in small and large pharmaceutical companies, such as a scientific coordinator at MMD (Lepetit),

Alexander Mankin is Distinguished Professor and Director of the Center for Biomolecular Sciences at the University of Illinois at Chicago (UIC), USA. He also holds the title of A. Neyfakh Collegiate Professor at the College of Pharmacy, UIC. Alexander’s research focuses on the mechanisms of action of ribosomal antibiotics. Through research carried out by his laboratory and collaborations with pharmaceutical companies, he has helped identify the sites and modes of action of several important classes of antibacterials, including oxazolidinones, ketolides,

Jeanne Marrazzo is Professor of Medicine and Director of the Division of Infectious Diseases at the University of Alabama, Birmingham, USA. She is internationally recognized for her research and education efforts in the field of sexually transmitted infections (STIs), especially as they affect women’s health. She is a fellow of the American College of Physicians and of the Infectious Diseases Society of America. She is board certified in infectious diseases. Jeanne conducts research on the human microbiome, specifically as it

Alita Miller is a Senior Director and Head of Bioscience at Entasis Therapeutics, a small biotech outside of Boston, USA, dedicated to the discovery and development of novel antibacterial agents to treat serious infections by resistant Gram-negative bacteria. At Entasis, Alita oversees both preclinical biology and developmental microbiology research. As a member of the senior leadership team, she is also involved in the strategic planning and execution of the company’s long-term research objectives. Alita has over 15 years’ experience in

Stefan Miller is a scientific consultant at Lysando AG and an independent consultant. He has significant experience as a chief scientific officer (CSO) and chief executive officer (CEO) in biotech companies and focuses on technology and product development including intellectual property strategy. Stefan co-founded Lysando AG in 2009 where he worked as CSO and led the research and development unit at Lisando GmbH as CEO, until 2014. That year he became a member of the advisory board of Lysando AG.

Alex O’Neill is Associate Professor at the University of Leeds, UK, and heads a research group whose aim is to better understand and address the problems presented by antibiotic resistance in bacterial pathogens. Alex’s twenty-year academic career has involved two particular areas of focus. The first is concerned with elucidation of the molecular mechanisms by which bacteria resist the effects of antibiotics. The second – and the one of greatest relevance to REVIVE – involves the discovery and biological characterization

Alastair Parkes currently leads medicinal chemistry in antibacterial drug discovery programmes at Evotec, a drug discovery alliance and development partnership company. Evotec is focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Alastair has worked at the company since 2006, first in the internal research department on proprietary central nervous system drug discovery programmes, followed by three years in oncology and, in antibacterial research since January 2014. Over the

Antonio (Toni) Perez is chief medical officer (CMO) and chairman of advisory boards in several pharmaceutical companies. In December 2017, he became CMO at MaxiVAX SA, a private Swiss clinical stage biotech company developing novel anti-cancer vaccines. He is also CMO for the development of agents in several infectious diseases (ID) at LASCCO/Combioxin in Geneva. Toni is Senior Medical Advisor at Abionic SA, a business uniquely positioned at the intersection of medical technology, biotechnology and nanotechnology. He is a member

David Pompliano is Founding Chief Scientific Officer (CSO) of Lodo Therapeutics, a drug discovery company based in New York. Since its inception in 2015, the company has focused on microbial metagenomics-based discovery, and synthetic biological manipulation of novel secondary metabolite biosynthetic pathways to produce new medicines. Lodo, backed by the Gates Foundation and the Accelerator Corporation, is developing new antibacterial agents to treat infections caused by Gram-negative pathogens and by Mycobacterium tuberculosis. David recently joined Accelerator Corporation as a Venture

Michael Pucci is Executive Director of Early Drug Discovery at Spero Therapeutics in Cambridge, Massachusetts. In addition to providing input into current R&D programmes, he explores potential new anti-infective programmes for the company pipeline and gathers competitive intelligence in the field. He also oversees non-dilutive funding opportunities and assists in the preparation of grant and contract applications. Michael has nearly 30 years’ experience in antibacterial drug discovery and development. Before co-founding Spero in 2014 he was the Executive Director of

Céline Pulcini is Full Professor of Infectious Diseases at Nancy University Hospital and leads a research team on stewardship at the University of Lorraine, Nancy, France. Her research focuses on antimicrobial stewardship and vaccination practices, with the aim of preventing the emergence of bacterial resistance to antibiotics. Céline is Secretary of ESGAP, the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Antimicrobial StewardshiP. She is working or has recently worked as an expert on the National

Daniel Ritz has been the Director and Senior Group Leader in the biology department of drug discovery at Idorsia Pharmaceuticals since it was created in June 2017. There he is responsible for preclinical antibacterial projects focusing on Gram-negative and broad-spectrum compounds. Daniel’s background is in biochemistry and bacterial genetics where he has focused on early discovery and lead optimization of antibacterial compounds, preclinical development, and microbiology aspects during later development stages. He spent 12 years at Actelion Pharmaceuticals, before the

Hans-Georg Sahl is Emeritus Professor at the University of Bonn. He has held various roles at the university since 1980 including research assistant, Assistant Professor for Medical Microbiology and was Professor of Medical and Pharmaceutical Microbiology until 2017. Hans-Georg has authored over 200 papers, mostly on the mechanisms of action of new antibiotic compounds. He is a named inventor on three patents. Hans-Georg studied biology and chemistry and earned a PhD in microbiology from the University of Bonn. He has

Sameeh M Salama is the Vice President (VP) of Business Development at Fedora Pharmaceuticals, VP of Business Development at the management and business consultancy firm, Brass Dome Ventures, and was formerly VP of NAEJA Pharmaceuticals. Since his move to industry in 1994, he has been heavily involved in antibacterial and antifungal research. His most recent research involved the initial discovery of a series of potent β-lactamase inhibitors which were later licensed to Roche and are now in clinical development. Sameeh

Stephen Senn is an independent consultant statistician with over 40 years’ experience. Stephen began his career in the National Health Service in England and as a lecturer in Scotland before joining the Swiss pharmaceutical industry in 1987. Since then his interests have been in statistical methods applied to drug development. He has held professorial posts at University College London and The University of Glasgow and most recently was head of the Competence Center for Methodology and Statistics at the Luxembourg

William (Bill) Shafer is Professor of Microbiology and Immunology at Emory University School of Medicine. He is a senior research career scientist at the Atlanta Veterans Affairs Medical Center, Director of the Antimicrobial Resistance and Therapeutic Discovery Training Program and Co-Director of the Emory Antibiotic Resistance Center. Bill has been on the faculty of Emory University since 1982, and continuously funded by the National Institutes of Health and the Department of Veterans Affairs since 1984 for his work on antibiotic

Karen Joy Shaw is Chief Scientific Officer at Amplyx Pharmaceuticals, a biotechnology company developing the first-in-class broad spectrum antifungal agent APX001, which has completed phase I intra-venous/oral clinical studies. She is also President of Hearts Consulting Group, where she consults on infectious disease drug discovery and development. Karen was previously Senior Vice President of Biology at Trius Therapeutics (acquired by Cubist Pharmaceuticals). At Trius, she led the microbiology development of the antibiotic tedizolid (Sivextro) and presented the drug’s microbiology and

Jared Silverman joined the Bill & Melinda Gates Medical Research Institute in January 2018 as Head of Translational Discovery. He was previously Senior Vice President of Research at Kaleido Biosciences, responsible for building a drug discovery pipeline to identify novel modulators of the human microbiome to treat and prevent disease. Jared’s whole career has focused on the discovery and development of novel antibiotics to treat serious drug resistant infections in hospitals. Before Kaledio, Jared spent 18 years at Cubist Pharmaceuticals,

Joyce Sutcliffe is an independent consultant with more than 35 years’ experience in antibiotic research and development. She is the former Senior Vice President (SVP) of Tetraphase Pharmaceuticals where she was responsible for managing discovery biology and preclinical development internally and with external contractors. She was part of the executive team involved in developing clinical strategies, marketing, budgeting resourcing, regulatory submissions, government contracts and, managing awarded contracts. Before joining Tetraphase, Joyce was Vice President of Research at the NanoBio Corporation where

Glenn Tillotson is a Partner at GST Micro, and a consultant to the pharmaceutical and diagnostic industries, providing advice on a range of topics covering preparatory and post-approval activities. Glenn has over 30 years’ pharmaceutical experience in clinical research, commercialization and, scientific communications including publications planning, strategic drug development, life cycle management and global launch programmes. Before becoming a consultant, Glenn was Senior Vice President (SVP) of Medical Affairs at Cempra, in charge of publication planning, medical information, opinion leader

Paul Tulkens is a member of the Louvain Drug Research institute and Emeritus Professor at the Université catholique de Louvain (UCL) in Brussels where his research focuses on cellular biology and toxicology, antibiotic pharmacodynamics and cellular pharmacokinetics and, new antibiotic discovery and development. As Professor of Pharmacology and Pharmacotherapy, Paul has also taught drug discovery and development and, rational therapeutic choices at UCL. He has also been a lecturer in human biochemistry and biochemical pathology at the Université de Mons-Hainaut.

Athanasios (Nassos) Typas currently leads a research group at the European Molecular Biology Laboratory (EMBL). His group works at the interface of systems microbiology and molecular mechanism, developing high-throughput genomics, genetics, chemical genetics and proteomics-based approaches to study bacterial cellular networks, and how bacteria interact with the environment and with each other. A key area of focus for the lab is antibiotics: their mode of action in the cell, their interactions with other drugs, the modes of resistance and their